Strategy in Practice

Mar 3, 2026

Strategy in Practice: In CY23, the global pharmaceutical industry is expected to increase at a compound annual growth rate (CAGR) of 7.5 percent, reaching USD 1570 billion. During the course of CY20, as COVID-19 came to a head, the pharmaceutical industry changed its focus to viral vectors in the biotherapy and vaccine sectors in order to develop effective vaccines and pharmaceutical medicines.

Following the release of the vaccine, the pharmaceutical industry will return to projects that were underway prior to the introduction of the vaccine. Many of these projects will benefit from the lessons learned by the industry during the COVID-19 outbreak, which will assist them to move forward more quickly and successfully.

The pharmaceuticals market in North America accounted for approximately 46 percent of the global market in CY20, making it the most populous region on the planet. The Asia-Pacific region accounted for around 26 percent of the total global medicines market in 2013. Africa had the smallest medicines market in the world, according to the World Drug Report.

Overall, the pharmaceutical business is expected to have significant growth in manufacturing capacity during the next few years, particularly in the United States. Geriatric and pediatric patients are receiving more attention, and the high incidence of cardiovascular disease, growing demand for home-based health care, and an increase in cancer and diabetes cases are all contributing to the rapid expansion of the global pharmaceutical manufacturing market, according to industry analysts’ strategy.

According to market experts, the pharmaceutical manufacturing market would grow at a compound annual growth rate (CAGR) of 12.8 percent from CY21 to CY30.

External analysis strategy

Porters 5 forces

Threats of New Entrants – High

It is becoming increasingly difficult for AstraZeneca Plc. to compete in the healthcare market due to new players offering clients innovative products and services, as well as new methods of doing things and presenting fresh value to customers. As a result, AstraZeneca Plc. needs to deal with these concerns and put in place effective barriers to protect its market position and competitive advantage.

Bargaining Power of Suppliers – High

The majority of healthcare companies source their raw materials from a varied set of vendors. Suppliers with a dominating position in a competitive market may be able to reduce AstraZeneca Plc’s margins by as much as 20% in a competitive environment. In the healthcare industry, the use of negotiation leverage by powerful suppliers in order to extract higher pricing from healthcare organizations is standard practice. The total profitability of the healthcare industry has been reduced as a result of increased supplier negotiating power.

Bargaining Power of Buyers- High

Buyers can be choosy. They want to get the best price on the best products. AstraZeneca’s long-term profitability was hampered as a result. The smaller and more powerful AstraZeneca Plc clients’ base, the more negotiating power and capacity to seek rising discounts and offers.

Threats of Substitute Products or Services- low

When new products and services meet customer expectations in a variety of ways, it can be difficult for firms to make money. Cloud storage services like Dropbox and Google Drive are increasingly replacing portable storage systems. An emerging product or service with a price proposal that is very different from what is available in the market represents a major threat to existing market share.

Rivalry among the Existing Competitors- Low

There is a direct correlation between the level of competition in an industry and its overall profitability. It’s a tough sector in which AstraZeneca Plc. operates. Overall, the organization’s long-term profitability suffers as a result of this rivalry.

Implications of Porter’s Five Forces on AstraZeneca Plc

By evaluating all five competing forces in the healthcare sector, AstraZeneca Plc. Strategists can gain a comprehensive understanding of what drives profitability in the industry. They have mastered the art of seeing game-changing trends early on and acting rapidly to capture the opportunity that presents itself. When AstraZeneca Plc.’s management fully comprehends the Porter Five Forces, it will be in a position to take advantage of that understanding.

PESTEL Analysis strategy

Political factors

Given that all legislation must be approved by the legislature, the government has a substantial impact on the restaurant industry. New health and safety rules, levies on imports, and a probable increase in the value-added tax are just some of the legislation that could have an influence on the restaurant sector. European Union legislation is also an option in this context. Strategy Challenges from the government and the legal system have a direct impact on AstraZeneca’s operations.

As a result of greater public awareness of the implications of aviation, the United Kingdom government is taking steps to guarantee that the industry reflects the environmental consequences of its operations. Proposals for an aviation tax, a fuel tax, and a value-added tax on airline tickets are gaining steam in Europe. Increased gasoline costs as well as tax policies implemented by the government in the United Kingdom have reduced the purchasing power of ordinary people in the country.

Considering all of the aforementioned considerations, it is possible that the company’s costs may increase, which will then be passed on to customers in the form of increased pricing.

Economic factors

Additionally, economic conditions on a national and international scale impact AstraZeneca. Customers’ self-perception and purchasing decisions are influenced by the state of the economy.

The purchasing power of potential customers and the status of the economy in the short and long-term have been affected by economic issues. Consider the following questions as a result:

Growth of the economy.
Inflationary pressures on the economy.
Inflationary pressures.
Amounts allotted in the budget.
The inflation rate.
Per capita, the number of people working.

Consumer spending on goods and services is affected by low interest rates, which have not been this low in 40 years. The higher the interest rate, the lower the rate of aggregate demand, which has a direct impact on the economy. When interest rates fall, the value of assets rises, making consumers richer.

Social Factors

Demographic shifts, shifts in how people live, work, and think, as well as cultural features of the macro environment, all fall under the heading of social variables. The size of the potential market is influenced by several factors:

Growth in the population
The distribution of ages in a population.
Safety is a top priority both inside and externally.
Attitudes of both internal and external transformation
Is there a clear understanding of what stakeholders anticipate from the unit’s performance?

Technological factors

AstraZeneca’s technology and business managers have been pushed into more strategic approaches to planning and management as a result of increased efficiency, effectiveness, and competitiveness, as well as novel applications of modern technology.

Environmental factors

Recycling is becoming more and more common in the United Kingdom, and it is no longer the exception. In the healthcare industry, some standards and expectations must be met, and AstraZeneca must plan to meet these expectations.

Customers’ activism has also played a role in the development of AstraZeneca’s strategy, which has been affected by rising customer awareness of environmental issues. As a responsible member of the community, customers look to AstraZeneca to uphold and even exceed the basic legal obligations.

Legal Factor

The procedure for enacting business law in the United Kingdom is described in this article. Whether or not these norms are consistent with those of international organizations such as the World Trade Organization and the European Union remains to be seen.

Over the past decade, the laws governing privacy and intellectual property rights have been increasingly linked, with data protection becoming an increasingly crucial part of both. AstraZeneca must consider whether or not the United Kingdom has a dependable mechanism in place to protect against data breaches before proceeding with a transaction.

Internal Analysis

VRIO Analysis

Valuable

An examination of the VRIO of AstraZeneca PLC shows that the corporation has substantial financial resources that can be invested in external prospects. To protect itself from external dangers, AstraZeneca PLC uses several measures.

Because of their uniqueness as a source of medicine, local food items are valuable to AstraZeneca PLC, according to the VRIO Analysis. Consequently, clients place great importance on these factors. Because of their uniqueness, these items are viewed as superior to their competitors.

Rare

It appears that AstraZeneca PLC’s financial resources are limited based on the results of the AstraZeneca PLC VRIO analysis. Only a limited percentage of businesses in the industry are provided with essential financial services, according to sector statistics.

AstraZeneca PLC is a pharmaceutical company. According to VRIO analysis, locally produced food is not uncommon. Some companies can easily provide this on the market if needed. Competitors AstraZeneca PLC can use these services in the same way as AstraZeneca PLC does, reducing the company’s competitive advantage. As a result, the availability of locally produced food does not have a negative impact on the competitive situation of AstraZeneca PLC in the market. Because of the importance of this resource, AstraZeneca PLC can continue to benefit from it.

Imitable

According to AstraZeneca PLC VRIO Analysis, the financial resources of AstraZeneca PLC are difficult to replicate. The company has collected these resources over the years for a long-term profit. It takes a lot of time for new entrants and competitors to accumulate these financial resources.

A VRIO analysis of AstraZeneca PLC found that duplication of local food products was less expensive. If they spend a lot of money on research and development, competitors can also get these. This does not require much prior knowledge either. As a result, the local food of AstraZeneca PLC gives you temporary benefits to competitors that can be gained over time.

Organisation

According to the VRIO Analysis of AstraZeneca PLC, its financial resources are organized to hold the largest amount. These resources are used wisely to invest in the right places, to seize opportunities and to fight risks. As a result, AstraZeneca PLC benefits from these services in the long run.

According to AstraZeneca PLC VRIO Analysis, AstraZeneca PLC patents are not well documented. These patents are not used by the organization at its highest level. If AstraZeneca PLC sells patented products before the expiration of the patents, it can turn a less-competitive competitive advantage into a long-term competitive advantage.

Value Chain Analysis

Primary Activities

AstraZeneca PLC enterprises are the mainstay of a number of products that manufacture and distribute pharmaceutical goods. It can be assumed that AstraZeneca PLC improved its performance by evaluating its core value chain functions, which are currently under investigation.

Inbound Logistics

The ability to receive, store, and distribute a product depends on the cooperation of the company’s suppliers. AstraZeneca PLC may have difficulty in product development stages if it does not analyze internal shipping. In order to perform in-bound logistics analysis, an entity must consider all stages of the production process, from immature items to final assets.

Operations

Export services provide the product to the customer through consultants. Items such as shipping, shipping and receiving are examples of foreign transport operations. AstraZeneca PLC can analyze and maximize results to gain competitive advantage and improve its business.

Outbound Logistics

Export services provide the product to the customer through consultants. Items such as shipping, shipping and receiving are examples of foreign transport operations. AstraZeneca PLC can analyze and expand outputs to gain competitive advantage and improve its business.

Marketing and Sales

In this section, AstraZeneca PLC will emphasize the advantages and disadvantages of the products it offers to convince customers that its offering is higher than that of its competitors’ offerings (Chinhoano, 2018). AstraZeneca PLC will not be able to generate value unless it engages in sales and marketing activities in addition to producing high quality products at competitive prices, according to analysts. Retailers and advertisers play an important role in this process.

Services

As a result of AstraZeneca PLC pre- and post-sales services, client loyalty will be improved. Post-sales services are very important to today’s customers as well as advertising and marketing efforts.

Secondary Activities

The key value chain functions are integrated and used for support functions. Analysis of support efforts for AstraZeneca PLC, as described below, may also be beneficial to the company.

Firm infrastructure

Business infrastructure means a variety of functions, including quality control, legal matters, accounting, financing, and strategic planning and management. AstraZeneca PLC can increase the value of the entire value chain with effective infrastructure management. AstraZeneca PLC has the ability to manage infrastructure operations (also known as overhead costs) to improve its market position.

Human Resources

AstraZeneca PLC can analyze personnel management by examining several HR components, such as hiring, selection, training, rewarding, performance management, and other personnel management functions. AstraZeneca PLC may be able to reduce competitive pressure by developing motivation, commitment. , and its staff expertise for better HR management.

Development of new technologies

Almost all of the functions associated with the value chain are technically supported in the modern era of high technology. AstraZeneca PLC must recognize the importance of technology development due to the integration of technology into production, distribution, marketing, and human resources.

Procurement

When it comes to value chain purchases, it refers to the processes involved in the purchase of inputs, which can include everything from machinery and equipment to immature goods, goods, raw materials, and other materials needed for finished production. product. The purchasing activities of AstraZeneca PLC should be carefully considered in order to increase the value of incoming, outgoing, and outgoing value chains, considering the company’s interactions with different value chain functions.

Strategic Recommendations and Evaluation

TOWS matrix

Threats

In some markets, the growing domination of local distributors is also dangerous because the competition pays local distributors huge profits.
As industry profits remain stable, there have been more competitors, which has reduced both profits and total sales over the past two years.
As a result, the company found it difficult to come up with new ideas and was forced to rely on products developed by competitors. Second, new products are not always delivered, making sales more flexible over time.
Competitive or disruptive technologies can pose a significant risk to the industry in the medium to long term.
Prosecutions may be brought against a company in multiple markets due to various laws and ongoing changes in product standards.
In China, rising wages, especially $ 15 an hour, and rising costs could put a strain on AstraZeneca PLC.
AstraZeneca PLC’s steady profit growth in some global markets is threatened by a shortage of skilled workers in such countries.
The profits of AstraZeneca PLC may be at risk due to rising raw material costs.

Opportunities

AstraZeneca PLC has the opportunity to develop a differentiated pricing strategy in the new market thanks to new technologies. Providing excellent service to existing customers while attracting new ones is a successful business environment.
Due to lower shipping costs, AstraZeneca PLC products can be cheaper, allowing the company to increase profits or win market share by transferring savings to customers.
Web channel – The organization has spent a lot of money over the last few years on the internet. AstraZeneca PLC is now able to reach more markets thanks to these investments. An organization can use this opportunity over the next few years to gain a deeper understanding of its customers and to meet their needs through data analytics.
After years of economic downturn and poor business growth rate, AstraZeneca PLC now has the opportunity to gain new customers and improve its market share.
A company’s consistent cash flow allows it to invest in new product lines. The company will be able to invest in new technologies and new product lines with more money in the bank. AstraZeneca PLC should be able to take advantage of this in other product areas.
AstraZeneca PLC has been able to join a new emerging market as a result of the adoption of new technology standards and the government’s free trade agreement.
Inflation – AstraZeneca PLC customers benefit from lower interest rates due to the lower inflation rate in the market.
New developments in consumer behavior may allow AstraZeneca PLC to enter new markets. New revenue streams can be generated and categories of new products can be added to the company’s product line.

Weaknesses

The product line provided by the company is insufficient. Due to a lack of alternatives, a new competitor may be able to gain market strength.
Lack of forecasting of a company’s product demand results in higher chances of missing out on opportunities compared to its competition. Compared to its competitors, the AstraZeneca PLC has a longer day list due to the fact that the firm has less experience in measuring demand and manages more innovations both in-house and in the distribution center, according to a recent report. The product may be well-marketed, but its shape and unique marketing proposal are not well defined, which could lead to attacks from competitors in this segment of the market.
Integration proved to be difficult for businesses with diverse work ethic. However, as mentioned earlier, despite the success of AstraZeneca PLC in consolidating small firms, the company has faced many challenges when it comes to merging businesses with different work ethic.
Inadequate financial and operational planning is widespread in the organization. In line with current asset and liquid asset estimates, a company has the potential to use its cash better than it does at the time of writing.
AstraZeneca PLC and A Net Contribution Average percentage of the company’s lower percentage compared to its competitors.
AstraZeneca PLC has had little success outside of its core industry due to the company’s current culture, despite the fact that it is a top organization in its fiel.

Strength

Thanks to the company’s specialized department of customer relationship management, it has achieved high levels of customer satisfaction and strong product equity among potential customers.
Innovation has a proven track record of success (brand rebranding).
AstraZeneca PLC has been able to achieve significant returns on capital expenditure while at the same time completing new projects due to the development of new revenue streams.
Consolidating related firms through mergers and acquisitions is a daunting task. It has been able to simplify its operation and build a strong supply chain due to its recent acquisition.
Over the years, AstraZeneca PLC has built a strong distribution network that allows the company to access most of its potential market share with its products.
AstraZeneca PLC has made it a goal to continue building the company’s portfolio of products for years to come. This is supported by the SWOT analysis of AstraZeneca PLC. If a company wants to grow into new product categories, having a strong product portfolio can be a huge benefit.
The Go to Market strategies used by the organization have proved to be incredibly successful.
Successfully Entering New Markets – AstraZeneca PLC has acquired the technology to enter new markets and establish successful businesses. The company has been able to establish new sources of revenue and differentiate the risks of the economic cycle due to its expansion into the markets where it currently operates.

Strategy

So that they may serve a global audience and become a global leader by entering new markets with their goods.

Sustainability

Sustainability acquisitions are a typical approach for organizations that wish to enter new markets and increase their reach. While it may seem counterintuitive, this technique helps acquirers not only gain market presence quickly but also lower their competitors’ capacity. TOWS matrix shows that in AZN, acquisition is the best way to penetrate the other market.

International corporations are eager to take advantage of the BRIC nations’ booming economies and expand their global operations. In spite of the fact that there is no economic agreement between BRIC countries, the summit’s participants regularly act in accordance with one another’s interests.

Feasibility

The company’s product will be available all over the world according to the suggested strategy, which aims to position it as a market leader.

Acceptability: Strategy in Practice

Risk

Company short-term commitments may not be met if the company’s current assets are exhausted in 2019. Despite a minor drop in leverage in 2019 compared to 2018, the corporation is still highly leveraged. There is also a decline in the interest cover, which indicates that the company’s debt commitments may be difficult to satisfy.

Return

How much profit has a corporation made by using its available resources? This is known as the Return on Capital Employed (ROCE). Capital employed is calculated as follows: share capital plus reserves plus long-term debt. The higher the ROCE percentage, the more successful the company is. There was a modest decline of ROCE for the company from 2018 to 2019, indicating that while operating profit increased in 2019, capital utilized increased at the same time. The company may therefore have difficulty reinvesting its profits in the business for the benefit of its stockholders.